Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTESOriginal contains colored plates: ALL DTIC reproductions will be in black and white.
ABSTRACTWe have made major progress towards the completion of the goals proposed in this award. In the first of the two Aims, we proposed to generate cell lines in which we stably suppressed XIAP using lentiviral-based RNA interference, and subsequently to constitute XIAP expression using mutants which are incapable of suppressing caspases. We have achieved this goal in PC-3 cells, and are well underway to generating similar clones in the three other cell lines we originally proposed. The first round of PC-3 derivatives have been injected into nude mice and we have exciting preliminary data supporting a role for XIAP in oncogenesis, and validating our model system for dissecting the properties of XIAP. In the second Aim, we proposed to examine XIAP expression in the TRAMP and Pten conditional transgenic murine models of prostate cancer. We have made great progress in the TRAMP system, and generated breeding colonies of Xiap-deficient, TRAMP mice. Finally, our studies to evaluate the effectiveness of a murine, XIAP-specific antisense oligonucleotide are now underway in TRAMP mice.